Skip to content

A study of management of Aaamvata with Erandadi kwath and Amritadi churna

A comparative clinical evaluation of Erandadi kwath and Amritadi churna in the management of Aamvata with special reference to Rheumatoid Arthritis - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080282
Enrollment
70
Registered
2025-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

None listed

Sponsors

Banaras Hindu University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to participate in the study. 2.Patients with age between 18-60 years. 3.The Patients of RA fulfills the diagnostic and assessment criteria, EULAR criteria 2010. 4.Both Seropositive and seronegative cases of RA. 5.Patients of both sexes. 6.Duration of illness at least 1-5 years.7.The patient with clinical feature of Aamvata mentioned in Samhita’s. Angamarda Aruchi Trishna Alasya Gaurava Jwara Apaka Angasoonata.

Exclusion criteria

Exclusion criteria: 1.Patients having severe ankylosed joints. 2.The patients of RA with major complications. 3.Patients of RA having other infective and non-infective joint disorders. 4.Patients with H/O less than 1 year and more than 5 years with established disease. 5.Patients having severe degree of deformity & complications. 6.Pregnant& lactating mother. 7.If patients having any allergy to the given drug. 8.Patients suffering from systemic disorder like (diabetes mellitus, cardiac disease, pulmonary tuberculosis, Essential hypertension, SLE, infectious arthritis.)

Design outcomes

Primary

MeasureTime frame
Relief in signs and symptoms of the disease. The main signs and symptoms are follows: stiffnes lack of eating desire fever thirst lethargy swelling heaviness in body and joints indigestionTimepoint: 3 Months with follow up at every 1 month

Secondary

MeasureTime frame
Changes in following- 1.On the basis of clinical sign and symptoms of grading scale 2.VAS scale 3.heamatological investigations(Anti ccp, RA factor, CBC, ESR,CRP,LFT,RFT 4.Assessment of severity of RATimepoint: 3 Months with follow up at every 1 month

Countries

India

Contacts

Public ContactProf Rajendra Prasad

Banaras Hindu University

rajendraprasad051@gmail.com9411471910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026